Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: AL355338 acts as an oncogenic lncRNA by interacting with protein ENO1 to regulate EGFR/AKT pathway in NSCLC

Fig. 4

Silencing AL355338 inhibited tumorigenesis, aerobic glycolysis and metastasis in vivo. A Tumor volumes were calculated every 5 days until the 3rd week. Tumor growth curves showed that sh-AL355338 group suppressed tumor growth compared with sh-NC group. B Tumor weight was measured after harvested from the nude mice with different treatments. C 18F-FDG micro-PET/CT images of living nude mice were conducted 3 weeks after injection. Comparison of the maximum standard 18F-FDG uptake value (SUVmax) of tumor tissues between the indicated groups. D Representative micro-PET/CT images showed higher 18F-FDG uptake in sh-NC xenografts compared with sh-AL355338 xenografts. E The xenografts were subjected to H&E and IHC staining with Ki-67, ENO1 and EGFR. Representative staining by FISH assay verified AL355338 knockdown efficiency. Scale bar, 100 μm. F Tumor cells were injected into nude mice through the tail vein to evaluate the lung homing potential of cells. Representative micro-CT scans images showed the gross lesion in lung tissues and HE staining presented metastatic nodules in the lungs from the different groups. Scale bar, 100 μm. G Summarized data on the number of metastatic lung nodules in mice with the indicated groups was counted under HE staining. Data shown are mean ± SD (n = 3) (*P < 0.05, **P < 0.01, ***P < 0.001)

Back to article page